Scan parameters
- Window: 2026-06-04 (1-day floor; most recent prior report was 2026-06-04)
- Passes: (a) conditionQuery PCNSL/PV/TCL/GvHD terms, Phase 2/3, all statuses; (b) tracked molecules × priority sponsors, no condition/phase filter; (c) priority sponsors × same conditions, phases EARLY_PHASE1/PHASE1/PHASE4/NA
- Pass (a): 9 hits; pass (b): 3 hits (2 already in a); pass (c): 2 hits (both already seen). Deduped unique: 10. In-scope candidates: 4.
1. NCT04984837 — Lacutamab in PTCL (TELLOMAK) | ENROLLMENT CLOSED
NCT04984837 · Innate Pharma / The Lymphoma Academic Research Organisation · Phase 2 · n=49
Signal: Enrollment closure — RECRUITING → ACTIVE_NOT_RECRUITING.
Version evidence: v8 (2026-06-02) changed OverallStatus to ACTIVE_NOT_RECRUITING; prior v7 (2026-04-15) was RECRUITING. Modules touched: Study Status, Study Design, Contacts/Locations. Status transition confirmed within window.
Context: TELLOMAK is the pivotal Phase 2 of lacutamab (IPH4102, anti-KIR3DL2 mAb, Innate Pharma) in relapsed/refractory T-cell lymphomas including nodal PTCL and Sézary syndrome. Enrollment closure at n=49 positions a readout within the next 12–18 months (PCD 2028-04-30). KIR3DL2 is selectively expressed on malignant T cells; this remains the only clinical program in this target class. Innate Pharma is a tracked sponsor (Phase 2/3 tier); Sanofi has a collaboration with Innate that includes lacutamab — a positive readout here would accelerate discussions around BLA filing strategy.
2. NCT05996627 — Belumosudil Pre-emptive cGvHD | SITE EXPANSION
NCT05996627 · Fred Hutchinson Cancer Center / Sanofi · Phase 2 · n=82 · RECRUITING
Signal: Site additions — Contacts/Locations module updated.
Version evidence: v14 (2026-06-03) touched Study Status + Contacts/Locations; prior v13 (2026-02-13) touched only Study Status. Status unchanged (RECRUITING both versions). Site additions confirmed within window.
Context: This trial tests belumosudil (ROCK2 inhibitor, Rezurock / KD025; Sanofi/Kadmon) as pre-emptive therapy for cGvHD — a step earlier than its approved 3L indication. If positive, it would expand the label into earlier-line cGvHD and widen the addressable market significantly. Ongoing site expansion with PCD 2028-04-30 suggests active accrual. Global scope: all new sites are in scope.
3. NCT07357727 — Pelabresib + Ruxolitinib in MF/PPV-MF (Novartis) | SITE EXPANSION
NCT07357727 · Novartis Pharmaceuticals · Phase 3 · n=460 · RECRUITING
Signal: Rapid consecutive site additions — Contacts/Locations module updated on two consecutive days.
Version evidence: v9 (2026-06-02) and v10 (2026-06-03) both touched Study Status + Contacts/Locations; OverallStatus RECRUITING in both. Site additions confirmed within window.
Context: Pelabresib (DAK539, BET inhibitor, originally Constellation/MorphoSys, acquired by Novartis) combined with ruxolitinib in myelofibrosis — including Post-polycythemia Vera MF (PPV-MF). PPV-MF is the natural endpoint of untreated/undertreated PV; a successful Phase 3 would pressure the upstream PV market. Ruxolitinib is a tracked molecule (PV + GvHD); Novartis is a priority sponsor. Pelabresib is not currently in the tracked_molecules list — if this trial progresses to NDA, consider adding it. Rapid site expansion on consecutive days suggests an aggressive global enrollment push.
Scope hygiene note: Consider adding pelabresib (DAK539) to tracked_molecules under the PV/MPN section given Novartis's Phase 3 investment in PPV-MF.
Pass (b) out-of-area catch — not promoted
NCT07252050 — Ruxolitinib-enhanced haplo HCT in sickle cell disease (Phase 1/2; Arkansas Children's Hospital; Incyte as collaborator; first posted 2025-11-26). Ruxolitinib is a tracked molecule; Incyte is a priority sponsor (as collaborator here, not lead). Condition is sickle cell disease — outside scope conditions. Update appears administrative (site/status verification). Not promoted. Incyte's ruxolitinib use in transplant/SCD settings is consistent with its established GvHD franchise; no strategic pivot signal detected.
Candidates reviewed and classified as noise
- NCT06271057 (golcadomide post-CAR-T in DLBCL; LYSARC/LSA; Phase 2): golcadomide is tracked but sponsor is academic (not BMS); condition is systemic DLBCL, not PCNSL. Out of scope for today's in-scope conditions. Not promoted.
- NCT03960840 (rapcabtagene autoleucel; Novartis priority sponsor; Phase 1/2; ACTIVE_NOT_RECRUITING): rapcabtagene is not a tracked molecule; conditions are CLL/SLL/DLBCL/ALL — not PCNSL specifically. First posted 2019. Not promoted.
- NCT07443137 (CLEAR-1; Stanford/Novartis collaborator; Phase 1; NOT_YET_RECRUITING): Novartis is collaborator; condition is LBCL (not CNS-specific); Phase 1 and Novartis is not lead sponsor. Not promoted.
- Remaining pass (a) hits (NCT07223021, NCT07328503, NCT03919240, NCT05800210): B-ALL or mixed heme malignancy conditions; outside scope. Not promoted.
|